have demonstrated that because of the resistance to anti-PD-1 treatment in metastatic melanoma, targeting of CD155 offers a novel strategy to promote the function of PD-1+CD8+ T cells, with improved response to anti-PD-1 therapy (50). The gene discussed is PDCD1; the disease is metastatic melanoma.